NSE · SUNREST · Pharmaceuticals
Sunrest Lifescience Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹33 Cr with net profit ₹2 Cr — a 6.04% net margin, versus 0.77% the period before.
Shareholding
As of 2026-06-30
- Promoter53.5%
- Public46.5%
484 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.96× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #83 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,73,821 Cr | 38.12 | 5.67 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,17,590 Cr | 211.88 | 3.41 | 11.27% | 14% |
| Lupin Limited | ₹1,10,742 Cr | 69.54 | 4.93 | 23.76% | 19.4% |
| Zydus Lifesciences Ltd. | ₹1,10,254 Cr | 20.3 | 4.07 | 18.59% | 18.86% |
| Mankind Pharma Limited | ₹1,08,354 Cr | 195.21 | 6.64 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,699 Cr | 346.21 | 18.23 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹94,969 Cr | 429.36 | 2.51 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹91,401 Cr | 99.22 | 2.41 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,537 Cr | 543.04 | 2.04 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹68,128 Cr | 288.21 | 4.93 | 16.66% | 15.65% |
| Sunrest Lifescience Ltd.(this company) | ₹30 Cr | 8.5 | 1.27 | 16.02% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashSunrest Lifescience Ltd. operates in the Pharmaceuticals sector. The company has a market capitalization of Rs 30 Cr. As of the latest available data, its 52-week high is Rs 54.17 and its 52-week low is Rs 26.37.
Positives
- +Revenue increased from Rs 16.9491 Cr in Mar 2021 to Rs 33.1229 Cr in Mar 2025.
- +Net Profit increased from Rs 0.1655 Cr in Mar 2021 to Rs 1.9998 Cr in Mar 2025.
- +The Return on Equity (ROE) is 16.02%, and Return on Capital Employed (ROCE) is 15.9364%.
Negatives
- −The profit margin is 0%, indicating no profit against revenue.
- −Public shareholding increased from 30.0895% in Mar 2024 to 46.4952% in Jun 2026, while promoter holding decreased from 69.9105% to 53.5048% in the same period.
- −EPS dropped from Rs 6.81 in Mar 2023 to Rs 0.68 in Mar 2024, before increasing to Rs 4.66 in Mar 2025.
- −No quarterly results disclosed since Jun 2023.
- −No dividend has been paid as the dividend yield is 0%.
Financial performance
Revenue increased from Rs 16.9491 Cr in Mar 2021 to Rs 33.1229 Cr in Mar 2025. Net profit also rose from Rs 0.1655 Cr in Mar 2021 to Rs 1.9998 Cr in Mar 2025. However, net profit saw a decrease in Mar 2024 to Rs 0.2257 Cr, recovering in Mar 2025.
Profitability & returns
The company reported a Return on Equity (ROE) of 16.02% and a Return on Capital Employed (ROCE) of 15.9364%. The Earnings Per Share (EPS) for the latest available annual period is Rs 3.6. The profit margin is 0% based on the provided data.
Balance sheet
Sunrest Lifescience Ltd. has a debt-to-equity ratio of 0.41, indicating a moderate level of debt relative to equity. The book value per share is Rs 27.45.
Ownership & pledges
Promoter holding stands at 53.5048% as of June 30, 2026. Public shareholding is 46.4952% for the same period. There is no information available regarding pledged promoter shares.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.